Opportunities this week:

After recent poor performance from Bank of Ireland’s stock (-13% since end of September) we reiterate our Buy recommendation with a reduced PT of €10.50 (25% upside) from €11.70.  
Following the election of Donald Trump and his nomination of Robert F Kennedy JR, vaccine related companies saw a negative reaction to their share prices, however we maintain our BUY rating for GSK with PT: £19.20.
On the back of recent data which signalled an improving outlook for non-residential construction in the US and given the continued positive infrastructure tailwind, we increase our CRH price target to £92.